With the success seen with the direct-acting antiviral drugs in hepatitis C, drug makers have shifted their sights toward potentially curative regimens for hepatitis B. At the recently concluded European Association for the Study of the Liver Meeting, one approach appearing to gain traction centered on reducing HBV surface antigen (HBsAg), perhaps even to undetectable levels.
The current standard of care for hepatitis B infection involves chronic therapy with one of several nucleotide analogues initially approved to treat HIV, but the experience in HCV shows that...
